Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. - Wikidata - wikimedia - TriplyDB

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

http://www.wikidata.org/entity/Q27853339

about

Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment CIViC database Recent Advances in Immunotherapy in Metastatic NSCLC Emerging therapeutic agents for lung cancer Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors Synthetic lethality in lung cancer and translation to clinical therapies Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Novel Microwave Torso Scanner for Thoracic Fluid Accumulation Diagnosis and Monitoring.Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-γ-induced immunologic dormancy of tumor-repopulating cells Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy.Immunotherapy for malignant pleural mesothelioma: current status and future directions.Tim-3 and its role in regulating anti-tumor immunity.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.The head and neck cancer immune landscape and its immunotherapeutic implications.Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma.Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC.Differential Expression of Immune Checkpoint Modulators on In Vitro Primed CD4(+) and CD8(+) T Cells.Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.

P2860

Q26738359-A6DCDBA1-F929-42E9-A071-2C47A172B27E Q27612411-90B2C371-2A01-4571-AB92-75EFF232078C Q28069323-3EBA0C41-99D6-4980-8632-AE54876F7B37 Q28070165-A4FBAEDC-1495-43B1-BA4E-8647A1BA190B Q28072532-2D3FF3A1-A34B-47CB-A646-F87C1A82B9C7 Q28072904-BC2F78B9-5CE1-41EF-AE1A-D4910B71793A Q28076071-DDC46ED2-F692-4E33-B547-7DAEBB596B63 Q30356467-1C0F86F5-5A7A-4F44-95E0-C7BE38B40373 Q33576409-37FC65EB-74A0-4810-9821-1938B37D35D0 Q33702231-0A214090-D6BD-4D56-A644-183BEE8A59DB Q33814411-ABF09737-6545-4051-A364-A86EB4212A09 Q33832752-340E8198-B071-426A-A65A-80A54BB258A7 Q33839054-859C8376-605E-48B5-B410-D5BCB299943F Q33890551-27953AE3-BF76-4F08-83FA-A3F241D8B9F8 Q33909020-8AAECEA6-7034-4755-818C-079FAC198844 Q36024656-B53A395F-C35E-4BA6-84B1-269418820BB6 Q37277198-47410F44-219E-45F3-93DE-9656F4C0D2C3 Q37351606-3342F8B7-C63D-4E61-AA6C-F0BF6DF90BBE Q37474092-DA227F3A-4522-4D6F-8846-661A9AD81116 Q37477267-D30BCE09-BE95-4B1C-ACD0-2F79C09B2A5F Q37552210-16C33C81-25D6-4810-B346-C42E56980370 Q37580120-CB2B51D0-C178-430B-87DD-B5ACA839902B Q37593573-35D62728-7DC7-435D-8439-97C734F91AFC Q37616503-5B0C07E6-60BF-4A0F-9496-347FBEB4F69F Q37664203-2F705810-BC64-4720-A9CD-E8DD6D874145 Q37671162-C4C23004-AE2A-4353-BBA1-403C66ABA464 Q37729313-545CF785-85AF-478F-9CA7-E5BE0F8DED96 Q38401891-0F7E4630-3B14-42C3-A8CB-EDB85A46AE29 Q38438763-3255CB96-80DF-4B44-9A97-03F0CF664433 Q38637044-F685FDED-13B8-4325-B102-62600C534086 Q38642853-D9960095-A8BC-40B7-A5CB-74DCFA1973C8 Q38646993-AD511F5B-80E1-43D7-9952-E16F86CBC109 Q38666253-939DBCBC-62E2-4E27-A3E8-C17EA33387B8 Q38687631-9F2172E4-89A3-4455-B7C0-0722C96296A7 Q38797202-E58977C3-9104-4FD7-B5CC-1F3957467982 Q38839108-26DFA8AB-3199-4D54-9703-3BFA151CE8C4 Q38840383-1CFBBDC9-EE65-4C4C-AA02-FDC9A3AEF786 Q38845203-6AEE4BB0-655E-492E-B5D5-276FC501FA45 Q38920328-AD72ED5C-4C57-47DE-A104-6B2A00B83BB2 Q38930244-18AC11B4-FCFA-446D-8A40-FE111C10B7EA

P2860

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

http://www.wikidata.org/entity/Q27853339

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Adaptive resistance to therape ...... lternative immune checkpoints.

@ast

Adaptive resistance to therape ...... lternative immune checkpoints.

@en

Adaptive resistance to therape ...... lternative immune checkpoints.

@nl

type

label

Adaptive resistance to therape ...... lternative immune checkpoints.

@ast

Adaptive resistance to therape ...... lternative immune checkpoints.

@en

Adaptive resistance to therape ...... lternative immune checkpoints.

@nl

altLabel

Adaptive resistance to therape ...... alternative immune checkpoints

@en

prefLabel

Adaptive resistance to therape ...... lternative immune checkpoints.

@ast

Adaptive resistance to therape ...... lternative immune checkpoints.

@en

Adaptive resistance to therape ...... lternative immune checkpoints.

@nl

P1433

Q27853339-0F9916F2-5159-4A90-A80E-85A81808B297

P1476

Q27853339-DE16A9F8-FBDD-4C1D-9E64-25F30D9B3668

P2093

Q27853339-1026F64D-8A25-4FF0-A896-7FD3F5B2FC08

Q27853339-15742786-A046-4BC4-A04C-ED7F8A524216

Q27853339-225998F4-4A47-4BBC-83E3-1BCD0E74F969

Q27853339-2642D380-17AF-46F8-80B2-599FB0C41EBE

Q27853339-4E25837F-5047-418D-8922-4055610A3AA5

Q27853339-50A75D79-5855-40B1-9B5E-4388F1751638

Q27853339-6AAAA90F-C6B3-40EF-A9AA-C2A0D528599E

Q27853339-83214078-2526-4078-8971-9962E8441748

Q27853339-83B77C79-801B-47EC-9FA8-92F4926C63F5

Q27853339-8891EF71-9B8F-44E6-A0E8-ECC37EDC0A00

P2860

Q27853339-0412DF00-9FFA-4FBE-B125-CCE9BDD74005

Q27853339-0DD524AA-A20B-440C-9C58-A00317EFA9A1

Q27853339-0ED45F48-A8DC-4551-BAE1-B7BF5A1CFED3

Q27853339-11B7F627-FCEC-4828-A48C-17DD4B1020EB

Q27853339-1611CC86-6F80-40F2-ADFF-4EEA804C3A4C

Q27853339-1945FE8D-29DD-4983-B3E9-937CF146A197

Q27853339-2AABF27C-06EB-4225-BB11-46C35137C922

Q27853339-2F282256-8AD9-4C70-960F-6AA263D7AA4C

Q27853339-31FEC485-FAF2-48BF-8364-66F6D6FDF177

Q27853339-3BBF9210-3953-40EC-8200-725D03ED9529

P2888

Q27853339-E372D645-0F77-4ED4-AAD0-54E0B562E0FE

P304

Q27853339-204825F0-4F2A-4F65-92C0-3B7AD71B4146

P31

Q27853339-B2015CB2-9BF1-406F-A621-D23EC6945758

P3181

Q27853339-A2E2FC64-E0DC-448A-A267-7417D38A75AB

P356

Q27853339-92D76B2B-F70F-42D6-8833-10969D2003F2

P407

Q27853339-F44E85B1-DF6F-4214-834E-37E936CA2EB9

P478

Q27853339-B4168357-64FE-43D8-B19A-85751CF269BC

P50

Q27853339-2323C6A6-D37A-4C80-A08B-A0976D26DA96

Q27853339-A78E8589-3ADE-4A11-9E3F-EF8B531FAD64

Q27853339-AB8EBDDA-88F6-4C46-A3DA-812BF1C4CD67

Q27853339-CF7E0C53-E7B6-409C-94CB-E82B1D9225BD

Q27853339-E7551D6B-5E85-4EE4-AC3D-51B62377C293

Q27853339-EB38A09B-8109-4F63-9753-4F7FE01C9F39

Q27853339-F4D257C8-678B-45CB-BB66-AC34CFEA32C2

P577

Q27853339-8179671B-28C3-441D-B553-5C4976D87ED8

P5875

Q27853339-E08E725D-F88E-4001-88CA-0DFF9E56EC73

P6179

Q27853339-E8E296A1-3E4B-4912-8CB5-964D3CE7601E

P698

Q27853339-434D8B48-1F63-440C-A879-E422932CBA9C

P932

Q27853339-E081787D-DE2F-4779-9E43-40D534353CC3

P3181

P356

P1433

Nature Communications

P1476

Adaptive resistance to therape ...... alternative immune checkpoints

@en

P2093

Amanda J Redig

http://www.w3.org/2001/XMLSchema#string

Bruce E Johnson

http://www.w3.org/2001/XMLSchema#string

F Stephen Hodi

http://www.w3.org/2001/XMLSchema#string

Glenn Dranoff

http://www.w3.org/2001/XMLSchema#string

Gordon J Freeman

http://www.w3.org/2001/XMLSchema#string

Grit S Herter-Sprie

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

Kevin A Buczkowski

http://www.w3.org/2001/XMLSchema#string

Mari Kuraguchi

http://www.w3.org/2001/XMLSchema#string

Meghana M Kulkarni

http://www.w3.org/2001/XMLSchema#string

P2860

Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

PD-1 and its ligands in tolerance and immunity

P2888

P304

10501

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

733192

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NCOMMS10501

http://www.w3.org/2001/XMLSchema#string

P407

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Sidhu Gangadharan

P577

2016-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

295179697

http://www.w3.org/2001/XMLSchema#string

P6179

1023222368

http://www.w3.org/2001/XMLSchema#string

P698

26883990

http://www.w3.org/2001/XMLSchema#string

P932

4757784

http://www.w3.org/2001/XMLSchema#string